copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Five-year survival in patients with extensive-stage small cell lung . . . Abstract Objectives: IMbrella A is a Phase III extension study that allowed rollover from Roche Genentech-sponsored atezolizumab trials, including IMpower133, a Phase I III trial of first-line atezolizumab or placebo plus carboplatin etoposide in extensive-stage small cell lung cancer We report outcomes from an exploratory analysis of IMpower133 with extended time-to-event data for patients
The Real-World Outcome of First Line Atezolizumab in Extensive-Stage . . . Abstract Purpose The addition of immune checkpoint inhibitors to chemotherapy has improved survival outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC) However, their real-world effectiveness remains unknown Therefore, we investigated the effectiveness of atezolizumab plus chemotherapy in ES-SCLC in actual clinical settings Materials and Methods In this multicenter
P47-1 The safety and efficacy of atezolizumab in small cell lung cancer . . . Atezolizumab has demonstrated enhanced safety and efficacy in individuals with SCLC Its mechanism involves the inhibition of PD-L1 protein signalling, leading to improved tumour-specific T cell immunity This systematic review aims to assess the safety and effectiveness of atezolizumab, taking into account potential adverse effects
Continued Atezolizumab Shows Durable Benefit in Pretreated ES-SCLC Continuation therapy with atezolizumab (Tecentriq) following progression on first-line chemo-immunotherapy produced promising efficacy and manageable safety in a small cohort of patients with extensive-stage small cell lung cancer (ES-SCLC), according to findings from a pooled analysis study published in Clinical and Experimental Medicine 1
For Small Cell Lung Cancer, Immunotherapy Drug Improves Survival In a clinical trial of patients with advanced small cell lung cancer (SCLC), atezolizumab (Tecentriq), combined with standard chemotherapy, modestly increased survival—the first trial in more than 20 years to show a survival improvement in this cancer
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination . . . "The FDA's Priority Review designation for Zepzelca in combination with atezolizumab as a first-line maintenance treatment highlights the urgent need for new approaches and the potential benefit of Zepzelca for patients with extensive-stage small cell lung cancer, a disease with limited therapeutic options and high unmet need," said Rob Iannone, M D , M S C E , executive vice president, global
IMforte: Maintenance Lurbinectedin + Atezolizumab Significantly . . . Results from the phase 3 IMforte trial show that maintenance therapy with a combination of lurbinectedin and atezolizumab helps patients with extensive-stage small cell lung cancer live months longer when compared with atezolizumab alone (Abstract 8006) The combination of lurbinectedin and atezolizumab was generally well tolerated, with no new or unexpected safety signals